• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Introduction to 5-(2-fluorophenyl)-1H-pyrazol-3-amine (CAS No. 502132-86-7) in Modern Chemical and Pharmaceutical Research

5-(2-fluorophenyl)-1H-pyrazol-3-amine, identified by the chemical abstracts service number CAS No. 502132-86-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the pyrazole class, a scaffold that is widely recognized for its biological activity and structural versatility. The presence of a fluorine atom at the 2-position of the phenyl ring introduces unique electronic and steric properties, making this molecule a promising candidate for further exploration in drug discovery and development.

The pyrazole core is a privileged structure in medicinal chemistry, exhibiting a broad spectrum of biological activities, including anti-inflammatory, antimicrobial, antiviral, and anticancer properties. The introduction of fluorine substituents into aromatic rings is a common strategy in drug design due to the ability of fluorine to modulate metabolic stability, binding affinity, and pharmacokinetic profiles of molecules. In the case of 5-(2-fluorophenyl)-1H-pyrazol-3-amine, the combination of these structural elements suggests potential therapeutic applications that warrant further investigation.

Recent advancements in computational chemistry and high-throughput screening have facilitated the identification of novel bioactive compounds. The structural features of 5-(2-fluorophenyl)-1H-pyrazol-3-amine make it an attractive candidate for virtual screening against various biological targets. For instance, studies have shown that pyrazole derivatives can interact with enzymes and receptors involved in signal transduction pathways relevant to diseases such as cancer and neurodegeneration. The fluorine atom at the 2-position may enhance binding interactions by improving lipophilicity and reducing metabolic degradation, thereby increasing the compound's bioavailability.

In vitro studies have begun to elucidate the pharmacological potential of 5-(2-fluorophenyl)-1H-pyrazol-3-amine. Preliminary experiments suggest that this compound exhibits inhibitory activity against certain kinases and other enzymes implicated in tumor growth and progression. The precise mechanism of action remains under investigation, but preliminary data indicate that it may interfere with critical signaling cascades by competing with natural substrates or by altering enzyme conformation. These findings align with the broader trend in oncology research, where small-molecule inhibitors targeting aberrant signaling pathways are being developed to improve patient outcomes.

The synthesis of 5-(2-fluorophenyl)-1H-pyrazol-3-amine presents an interesting challenge due to the need to introduce both the pyrazole ring and the fluorinated phenyl moiety while maintaining regioselectivity. Modern synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have enabled efficient access to complex heterocyclic structures like this one. These techniques allow for modular construction of the molecular framework, enabling chemists to explore analogs with modified substituents to optimize biological activity.

The role of fluorine in medicinal chemistry extends beyond mere structural modification; it also influences pharmacokinetic properties such as absorption, distribution, metabolism, excretion (ADME), and toxicity (DTX). Fluorinated compounds often exhibit improved pharmacological profiles due to their enhanced stability against metabolic degradation. For example, fluoroaromatics may resist cytochrome P450-mediated oxidation more effectively than their hydrogenated counterparts, leading to longer half-lives and sustained therapeutic effects. This characteristic makes 5-(2-fluorophenyl)-1H-pyrazol-3-amine a particularly compelling candidate for further development.

Current research is also exploring the potential applications of 5-(2-fluorophenyl)-1H-pyrazol-3-amine in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Pyrazole derivatives have been shown to modulate neurotransmitter systems and protect against oxidative stress-induced neuronal damage. The fluorine atom may enhance penetration across the blood-brain barrier (BBB), a critical factor for treating central nervous system disorders. Ongoing studies aim to validate these hypotheses through both preclinical models and clinical trials.

The integration of machine learning and artificial intelligence into drug discovery has accelerated the identification of novel therapeutic agents. Predictive models can assess the potential bioactivity of compounds like 5-(2-fluorophenyl)-1H-pyrazol-3-amine based on their structural features before experimental validation is required. This approach not only saves time but also allows for rapid optimization of lead compounds by identifying key structural determinants of activity. Such computational tools are becoming indispensable in modern pharmaceutical research.

Future directions for research on 5-(2-fluorophenyl)-1H-pyrazol-3-amine include exploring its potential as an intermediate in multi-target drug design strategies. By combining it with other bioactive scaffolds or functional groups, chemists may develop hybrid molecules with enhanced therapeutic efficacy or reduced side effects. Additionally, investigating its interaction with protein targets at an atomic level using techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy will provide deeper insights into its mechanism of action.

The safety profile of any new compound is paramount before it can enter clinical development. While preliminary data suggest that 5-(2-fluorophenyl)-1H-pyrazol-3-amine is well-tolerated in vitro, further toxicological studies are necessary to assess its potential risks in vivo. These studies will evaluate parameters such as acute toxicity, chronic exposure effects, genotoxicity, and carcinogenicity. A comprehensive understanding of its safety profile will be essential for advancing it through regulatory approvals.

In conclusion,5-(2-fluorophenyl)-1H-pyrazol-3-amine (CAS No. 502132-86-7) represents a promising scaffold for pharmaceutical development due to its unique structural features and demonstrated biological activity. The combination of computational methods, synthetic chemistry innovations, and preclinical investigations positions this compound as a valuable asset in modern drug discovery efforts aimed at addressing unmet medical needs across multiple therapeutic areas.

• 1025447-54-4(3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride)
• 1242422-48-5(3-(4-Fluorophenyl)-1H-pyrazol-5-amine)
• 766519-89-5(5-(3-fluorophenyl)-1H-pyrazol-3-amine)
• 97052-86-3(3-(2-fluoro-5-methylphenyl)-1H-pyrazol-5-amine)
• 1028842-99-0(5-Amino-3-(3-fluorophenyl)pyrazole)
• 878630-54-7(1H-Pyrazol-3-amine, 5-(fluorophenyl)-)
• 397844-80-3(5-(2,6-Difluorophenyl)-1H-pyrazol-3-amine)
• 72411-52-0(5-(4-fluorophenyl)-1H-pyrazol-3-amine)
• 929635-71-2(5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE)
• 1384537-81-8(3-(2,3-difluorophenyl)-1H-pyrazol-5-amine)